Conference Coverage
Conference Coverage
CLL: Venetoclax-obinutuzumab combo effective long term
Progression-free survival benefit of 1 year with venetoclax-obinutuzumab is sustained long term in chronic lymphocytic leukemia, trial analysis...
Conference Coverage
`Remarkable’: CAR T therapy for CLL/SLL
Primary analysis of the TRANSCEND CLL 004 trial showed that a single dose of CAR T therapy achieved durable responses in CLL and SLL, with a...
Conference Coverage
PMBCL: Postremission, patients may safely skip radiation
Among patients who had achieved complete remission of primary mediastinal B-cell lymphoma with chemotherapy, the largest study of its kind found...
Conference Coverage
Frontline CLL treatment: Avoiding adverse events
Single-agent frontline therapy helps patients with CLL live longer, but those at high risk of relapse may benefit from multiagent treatment.
Conference Coverage
CML: Preventing chemo-induced vascular toxicity
Cardiologists advise on how to ward off side effects linked to 2 TKI treatments for chronic myeloid leukemia.
Conference Coverage
CLL phase 3 study: Zanubrutinib bests ibrutinib
The second-generation Bruton’s tyrosine kinase inhibitor zanubrutinib outperformed ibrutinib in a phase 3 study.
Conference Coverage
MCL: Ibrutinib could become the ‘new standard’
New research showed ibrutinib outperformed HSCT for treating younger patients with mantle cell lymphoma.
Conference Coverage
ASH 2022: New clinical data challenge long-held assumptions
Fresh research to be unveiled at the 2022 American Society of Hematology conference seems to overturn conventional wisdom across a range of issues...
Conference Coverage
Many die waiting for `last-chance’ therapy
Blood cancer patients, especially those with myeloma, face hospice and death while awaiting CAR T-cell therapy.
Conference Coverage
‘Superior’ CLL regimen cuts chemo in half
Where chemo is still used to treat CLL, this three-cycle regimen combined with ibrutinib and obinutuzumab shows progression-free and overall...